MetLife Investment Management’s Caribou Biosciences CRBU Stock Holding History

MetLife Investment Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-24,404	Closed	-$38.8K	–	2793
2024 Q4	$38.8K	Buy	24,404 +9,148	+60%	+$18.4K	﹤0.01%	2758
2024 Q3	$29.9K	Sell	15,256 -33,503	-69%	-$68.6K	﹤0.01%	2802
2024 Q2	$80K	Buy	48,759 +8,069	+20%	+$25.8K	﹤0.01%	2682
2024 Q1	$209K	Hold	40,690	–	–	﹤0.01%	2182
2023 Q4	$233K	Hold	40,690	–	–	﹤0.01%	2156
2023 Q3	$194K	Buy	40,690 +9,687	+31%	+$60.1K	﹤0.01%	2227
2023 Q2	$132K	Hold	31,003	–	–	﹤0.01%	2522
2023 Q1	$165K	Hold	31,003	–	–	﹤0.01%	2339
2022 Q4	$195K	Hold	31,003	–	–	﹤0.01%	2257
2022 Q3	$327K	Hold	31,003	–	–	﹤0.01%	1937
2022 Q2	$168K	Hold	31,003	–	–	﹤0.01%	2433
2022 Q1	$285K	Buy	31,003 +23,472	+312%	+$247K	﹤0.01%	2124
2021 Q4	$114K	Hold	7,531	–	–	﹤0.01%	2365
2021 Q3	$180K	Buy	+7,531	New	+$184K	﹤0.01%	2164

Other funds holding CRBU

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MetLife Investment Management's CRBU Position: Q1 2025 in Review

MetLife Investment Management sold out of Caribou Biosciences (CRBU) in Q1 2025, closing a stake of 24,404 shares — an estimated $38.8K sold.

MetLife Investment Management first reported a position in CRBU in Q3 2021 and held it in 14 quarters. The position peaked at $327K in Q3 2022. 131 funds tracked by Wall St. Rank hold CRBU as of Q1 2025.

MetLife Investment Management reported no remaining Caribou Biosciences position as of Q1 2025 after selling out during the quarter.
MetLife Investment Management sold 24,404 Caribou Biosciences shares in Q1 2025, an estimated $38.8K.
MetLife Investment Management first reported a position in Caribou Biosciences in Q3 2021 and held it in 14 quarters.
MetLife Investment Management's Caribou Biosciences position peaked at $327K in Q3 2022.
131 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2025.

Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.